Navigation Links
Neurochem Annual and Special Meeting of shareholders
Date:4/11/2008

Neurochem will host a live Web conference on Tuesday, April 15, 2008, at ------------------------------------------------------------------------

10:00 AM ET -----------

LAVAL, QC, April 11 /PRNewswire-FirstCall/ - Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), as well as members of senior management, cordially invite you to attend the Company's Annual and Special Meeting of shareholders on Tuesday, April 15, 2008. The meeting will take place at 10:00 A.M. ET, in the Maxwell-Cummings Auditorium of the Michal and Renata Hornstein Pavilion of the Montreal Museum of Fine Arts, located at 1379 Sherbrooke Street West, Montreal, Quebec.

Following the Company's presentation, attendees will have the opportunity to interact with management through a question and answer period.

Live Web Cast

Neurochem's Annual and Special Meeting will be webcast live at 10:00 A.M. ET, on Tuesday, April 15, 2008. The live Web Cast (audio and visual) will be available on the Company's Web site at http://www.neurochem.com. The telephone numbers to access the audio portion of the meeting only are 514-861-0916 or 1-866-303-7746.

A replay of the Web Cast (audio and visual) will be available three hours following the conclusion of the presentation, and this until April 22, 2008. The telephone numbers to access the audio replay are 514-861-2272 or 1-800-408-3053, passcode 3257716#.

Please note that the dial-in numbers and Web Cast will not allow participants to ask questions. Please dial-in or access Neurochem's Web site approximately 15 minutes prior to the beginning of the presentation.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
2. Neurochem announces departure of two members of management team
3. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
4. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
5. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
6. Neurochem to present at JPMorgan Healthcare Conference
7. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
10. Neurochem reports results for third quarter of fiscal 2007
11. With annual deaths from malaria on the rise: Scientists ask where is all the money going?

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...LOSANGELES,Nov.25/PRNewswire-USNewswire/--TheBlack...odetermineexecutiveleadershipfor2010. ,, Thenew...cialtiesinpublicpolicy,law,finance,governmenthealt...eBoardalsocomesfromawiderangeofpersonalbackgrounds...melivingwithHIVthemselves,andrepresentingmultiplea...
(Date:11/25/2009)...erm survivors of testicular cancer who were treate...e side effects, including neurological side effect...t treated with chemotherapy, according to a new st...f the National Cancer Institute . , Marianne Bry... University Hospital, in Bergen, Norway, and colle...
(Date:11/25/2009)...tress increase blood pressure? This simple questi... years. New Stress-related gene Modulates High Bl...blood pressure? This simple question has been the...w research has for the first time established a li...pressure response to stress in mice as well as hum...
(Date:11/25/2009)... Evaluation and treatment clinics... Woodstock (Vocus) November 25, 2009 -- Centegr...vaccines and H1N1 vaccine shots at four Centegra P...r shipment of vaccine has arrived. The clinics are...and McHenry and will be open as follows: , &nb...
(Date:11/25/2009)...positive note, CDC sees few signs of trouble with ...5 (HealthDay News) -- The ongoing H1N1 swine flu p... pneumonias among younger patients, a U.S. health ...crease in serious pneumococcal infections around t...tional Center for Immunization and Respiratory Dis...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4
...mericans diagnosed with primary open angle glaucom...or the condition according to a study. Th...rapy use in the U.S. to utilize longitudinal data ...ed 65 and older by analyzing data collected from 1...
...nistration (FDA) today issued a formal written req...l devices remaining in the marketplace, including...ns. On April 17, 2007, U.S. Marshals, at F...'s manufacturing processes. During the seizure, Sh...
...ght not only face the risk of developing health di...they are also likely to face the risk of developi...r 17 years, the study - by researchers at the Canc...for men and 85 for women significantly increases c...
...nistration (FDA) is warning pharmaceutical manufac...essionals who compound medications to be especial... commonly used worldwide in liquid over-the-counte...the agency is issuing guidance to industry recomme...
... as the most brisk walkers in the world, as the sp...en percent in the last decade. In a sampl... on top followed by citizens of Copenhagen, Madrid...the study. But walking fast is not good f...
...Bobby Robson is ready to fight against cancer for ...ho said that he was diagnosed with cancer for the ...y last week after cancerous nodules were discovere...e greatest news I've ever had but I have fought ha...
Other Medicine News:Health News:FDA Advises Manufacturers to Test Glycerin for Possible Contamination 2Health News:Bobby Robson Diagnosed With Cancer for Fifth Time 2
(Date:11/25/2009)...stCall/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevi...sruptivesurgicaltreatmentsforthespine,announcedtod...,2009,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwil...Company,sproductsandwillincludecommentsfrommanagem...l-innumbersare1-877-407-4018fordomesticcallersand1...
(Date:11/25/2009)...portlinker.comannouncesthatanewmarketresearchrepor...elivery-USMarketTrends&Analysis http://www.re...-US-Market-Trends--Analysis.html ,, TheUSintra...erapeuticapplicationsfromthedeliveryofconventional...euticdrugs.Thefutureofthetechnologyhingesontotheef...
(Date:11/25/2009)...ewswire/-- ChemoCentryx,Inc.,announcedtodaythatPh...ProspectiveRandomizedOralTherapyEvaluationinCrohn,...swithmoderate-to-severeCrohn,sdiseasedemonstratedc...profile.Thestudydemonstratedevidenceofclinicaleffi...pointdecreaseintheCrohn,sDiseaseActivityIndex(CDAI...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Study finds colorectal cancer rates increasing worldwide 8769 1Study finds colorectal cancer rates increasing worldwide 8769 2Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 1Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 2Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 3Lumbar Spinal Stenosis Surgery at the Olympia Medical Center 48340 1Lumbar Spinal Stenosis Surgery at the Olympia Medical Center 48340 2
... for Presentation at 47th ICAAC on ..., Sept. 4 Ardea Biosciences,Inc. (Pink Sheets: AR...eted,Phase 1 single-ascending-dose, multiple-ascen...es of RDEA806, a novel HIV non-nucleoside reverse,...eers. The data from these Phase 1 clinical trials...
...ive analysis of,clinical trials known as a meta-an...tent was associated with significantly lower risks...mpared to the Taxus Stent out to 30,months after a...randomized,clinical trials and 8,695 patients, the...ed on the Journal of the American College of Cardi...
Other Medicine Technology:Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 2Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 2Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 4
Anterior Stromal Puncture Cannula, 25 g
Viscoelastic Cannula, 23 g. Angled
Anterior Chamber Needle, 21 g
Anterior Chamber Needle, 25 g. Angled
Medicine Products: